The European Patent Office (EPO) has granted a European Patent to CovalX AG for a new method to characterize the effect of potential drugs on protein-protein interactions

Zürich – June 26th 2012

The European Patent Office (EPO) has granted a European Patent (08717827.3-2404) to CovalX AG for a new method to characterize the effect of potential drugs on protein-protein interaction. The patent is based on the used of CovalX’s proprietary technology.

The method of the invention is adapted to high through put analysis and is based on a specially developed cross-linking chemistry and ultra high mass MALDI mass spectrometry. This new method allows a fast and direct analysis of potential therapeutic targeting protein-protein interactions. The method can be applied in most formulation buffers and allows to characterize IC50 of drug candidates.

The patented method has been recently implemented in CovalX CRO laboratory and help pharmaceutical and biotechnology companies to evaluate drug candidates.

CovalX
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.